{"id":59082,"date":"2024-03-21T22:02:26","date_gmt":"2024-03-21T21:02:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/"},"modified":"2024-03-21T22:02:26","modified_gmt":"2024-03-21T21:02:26","slug":"axonics-provides-update-on-inter-partes-review-proceedings","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/","title":{"rendered":"Axonics Provides Update on Inter Partes Review Proceedings"},"content":{"rendered":"
\n

IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe PTAB issued its decision with respect to Patent Nos. 8,626,314 (\u201cthe \u2018314 patent\u201d) and 8,036,756 (\u201cthe \u2018756 patent\u201d). Medtronic has asserted these patents, which expired in 2021 and 2022, against Axonics\u2019 proprietary tined lead design. Today, the PTAB invalidated 10 of the 15 challenged claims in Medtronic\u2019s \u2018314 patent and declined to invalidate the challenged claims in the \u2018756 patent over one Administrative Patent Judge\u2019s dissenting opinion. The district court case where Medtronic has asserted these patents is currently stayed based on these IPRs as well as pending IPRs on other Medtronic asserted patents. Axonics plans to seek review of the PTAB\u2019s finding that the remaining claims were not unpatentable.<\/p>\n

\n\u201cWe are pleased with the PTAB\u2019s decision finding numerous claims of the \u2018314 patent unpatentable,\u201d said Raymond W. Cohen, chief executive officer. \u201cAxonics will continue to vigorously defend itself against Medtronic\u2019s claims while we remain focused on fulfilling our mission of changing the lives of patients suffering from bladder and bowel dysfunction.\u201d<\/p>\n

\nAbout Axonics<\/b><\/p>\n

\nAxonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the 2023<\/a> Financial Times ranking of the fastest growing companies in the Americas after being ranked No. 1 in 2022<\/a>.<\/p>\n

\nAxonics\u00ae<\/sup> sacral neuromodulation systems provide adults with overactive bladder and\/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company\u2019s best-in-class urethral bulking hydrogel, Bulkamid\u00ae<\/sup>, provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. For more information, visit www.axonics.com<\/a>.<\/p>\n

\nCautionary Statement Regarding Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words like \u201cmay,\u201d \u201cwill,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cfuture,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cgoal,\u201d \u201cseek,\u201d \u201cendeavor,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201ccontinue,\u201d and variations of such words and similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, assumptions, and uncertainties, including, but not limited to, risks related to: Axonics\u2019 ability to consummate the transactions contemplated by the Agreement and Plan of Merger, dated January 8, 2024 (the \u201cMerger Agreement\u201d), by and among Axonics, Boston Scientific Corporation (\u201cBoston Scientific\u201d), and Sadie Merger Sub, Inc., a wholly owned subsidiary of Boston Scientific (\u201cMerger Sub\u201d), providing for the merger of Merger Sub with and into Axonics with Axonics continuing as the surviving company and a wholly owned subsidiary of Boston Scientific (the \u201cMerger\u201d), in a timely manner or at all; the risk that the Merger Agreement may be terminated in circumstances requiring the payment by Axonics of a termination fee; the satisfaction (or waiver) of the conditions to the closing of the Merger; potential delays in consummating the Merger; the occurrence of any event, change or other circumstance or condition that could give rise to termination of the Merger Agreement; Axonics\u2019 ability to timely and successfully realize the anticipated benefits of the Merger; the ability to successfully integrate the businesses of Axonics and Boston Scientific; the effect of the announcement or pendency of the Merger on Axonics\u2019 current plans, business relationships, operating results and business generally; the effect of limitations placed on Axonics\u2019 business under the Merger Agreement; significant transaction costs and unknown liabilities; litigation or regulatory actions related to the Merger Agreement or Merger; FDA or other U.S. or foreign regulatory or legal actions or changes affecting Axonics or Axonics\u2019 industry; the results of any ongoing or future legal proceedings, including the litigation with Medtronic, Inc., Medtronic Puerto Rico Operations Co., Medtronic Logistics LLC and Medtronic USA, Inc. (the \u201cMedtronic Litigation\u201d); any termination or loss of intellectual property rights, including as a result of the Medtronic Litigation; introductions and announcements of new technologies by Axonics, any commercialization partners or Axonics\u2019 competitors, and the timing of these introductions and announcements; changes in macroeconomic and market conditions and volatility, including the risk of recession, inflation, supply chain constraints or disruptions and rising interest rates; and economic and market conditions in general and in the medical technology industry specifically, including the size and growth, if any, of Axonics\u2019 markets, and risks related to other factors described under \u201cRisk Factors\u201d in other reports and statements filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including Axonics\u2019 most recent Annual Report on Form 10-K, which is available on the investor relations section of Axonics\u2019 website at www.axonics.com<\/a> and on the SEC\u2019s website at www.sec.gov<\/a>. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by these forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.<\/p>\n

\nThe forward-looking statements included in this press release are made only as of the date of this press release, and except as otherwise required by federal securities law, Axonics does not assume any obligation nor does it intend to publicly update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.<\/p>\n

\nAdditional Information and Where to Find It<\/b><\/p>\n

\nIn connection with the contemplated Merger, Axonics filed on February 22, 2024 with the SEC a definitive proxy statement relating to a special meeting of Axonics\u2019 stockholders to be held for the purpose of obtaining stockholder approval of the Merger Agreement and other related matters (the \u201cProxy Statement\u201d). The Proxy Statement was mailed to Axonics\u2019 stockholders on or about February 22, 2024. Axonics may also file other documents with the SEC regarding the contemplated Merger. This document is not a substitute for the Proxy Statement or any other document that Axonics has filed or may file with the SEC in connection with the contemplated Merger. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF AXONICS ARE URGED TO READ THE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS THERETO, ANY OTHER SOLICITING MATERIALS AND ANY OTHER DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC IN CONNECTION WITH THE CONTEMPLATED MERGER OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT BECAUSE THEY CONTAIN OR WILL CONTAIN, AS APPLICABLE, IMPORTANT INFORMATION ABOUT AXONICS, BOSTON SCIENTIFIC AND THE CONTEMPLATED MERGER. Investors and security holders may obtain free copies of the Proxy Statement and other filings containing important information about Axonics on the SEC\u2019s website at www.sec.gov<\/a>, on Axonics\u2019 website at www.axonics.com<\/a> or by contacting Axonics\u2019 Investor Relations department via email at IR@axonics.com<\/a>.<\/p>\n

\nParticipants in the Solicitation<\/b><\/p>\n

\nAxonics and its directors and executive officers may, under SEC rules, be deemed participants in the solicitation of proxies from the stockholders of Axonics in connection with the contemplated Merger. Information regarding the identity of potential participants in the solicitation of proxies in connection with the proposed Merger, and their direct or indirect interests, by security holdings or otherwise, is included in the Proxy Statement. Additional information regarding Axonics\u2019 directors and executive officers is contained in the Proxy Statement, Axonics\u2019 Definitive Proxy Statement on Schedule 14A<\/a> for Axonics\u2019 2023 Annual Meeting of Stockholders, which was filed with the SEC on May 1, 2023 (and specifically, the following sections: \u201cSecurity Ownership of Certain Beneficial Owners, Executive Officers and Directors\u201d, \u201cCertain Relationships and Related-Party Transactions\u201d, \u201cExecutive Officers\u201d, \u201cProposal 1\u2013Election of Directors\u201d, \u201cDirector Compensation\u201d, and \u201cExecutive Compensation\u201d) and in Axonics\u2019 Current Report on Form 8-K<\/a>, which was filed with the SEC on October 4, 2023. To the extent holdings of the Company\u2019s securities by the directors or executive officers have changed since the amounts set forth in the Proxy Statement, such changes have been or will be reflected on Initial Statement of Beneficial Ownership of Securities on Form 3, Statement of Changes in Beneficial Ownership on Form 4, or Annual Statement of Changes in Beneficial Ownership on Form 5 filed with the SEC, which are available at EDGAR Search Results (sec.gov). These documents (when available) are available free of charge as described in the preceding section.<\/p>\n

Contacts<\/b> <\/p>\n

\nNeil Bhalodkar
\n
IR@axonics.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting. The PTAB issued its decision with respect to Patent Nos. 8,626,314 (\u201cthe \u2018314 patent\u201d) and 8,036,756 (\u201cthe \u2018756 patent\u201d). Medtronic … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59082","6":"format-standard","7":"category-industry"},"yoast_head":"\nAxonics Provides Update on Inter Partes Review Proceedings - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Axonics Provides Update on Inter Partes Review Proceedings - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting. The PTAB issued its decision with respect to Patent Nos. 8,626,314 (\u201cthe \u2018314 patent\u201d) and 8,036,756 (\u201cthe \u2018756 patent\u201d). Medtronic ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-21T21:02:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240321796123\/en\/788134\/22\/Axonics_Logo_-_Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-provides-update-on-inter-partes-review-proceedings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-provides-update-on-inter-partes-review-proceedings\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Axonics Provides Update on Inter Partes Review Proceedings\",\"datePublished\":\"2024-03-21T21:02:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-provides-update-on-inter-partes-review-proceedings\\\/\"},\"wordCount\":1383,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-provides-update-on-inter-partes-review-proceedings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240321796123\\\/en\\\/788134\\\/22\\\/Axonics_Logo_-_Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-provides-update-on-inter-partes-review-proceedings\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-provides-update-on-inter-partes-review-proceedings\\\/\",\"name\":\"Axonics Provides Update on Inter Partes Review Proceedings - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-provides-update-on-inter-partes-review-proceedings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-provides-update-on-inter-partes-review-proceedings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240321796123\\\/en\\\/788134\\\/22\\\/Axonics_Logo_-_Color.jpg\",\"datePublished\":\"2024-03-21T21:02:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-provides-update-on-inter-partes-review-proceedings\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-provides-update-on-inter-partes-review-proceedings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-provides-update-on-inter-partes-review-proceedings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240321796123\\\/en\\\/788134\\\/22\\\/Axonics_Logo_-_Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240321796123\\\/en\\\/788134\\\/22\\\/Axonics_Logo_-_Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-provides-update-on-inter-partes-review-proceedings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Axonics Provides Update on Inter Partes Review Proceedings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Axonics Provides Update on Inter Partes Review Proceedings - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/","og_locale":"en_US","og_type":"article","og_title":"Axonics Provides Update on Inter Partes Review Proceedings - Pharma Trend","og_description":"IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting. The PTAB issued its decision with respect to Patent Nos. 8,626,314 (\u201cthe \u2018314 patent\u201d) and 8,036,756 (\u201cthe \u2018756 patent\u201d). Medtronic ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/","og_site_name":"Pharma Trend","article_published_time":"2024-03-21T21:02:26+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240321796123\/en\/788134\/22\/Axonics_Logo_-_Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Axonics Provides Update on Inter Partes Review Proceedings","datePublished":"2024-03-21T21:02:26+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/"},"wordCount":1383,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240321796123\/en\/788134\/22\/Axonics_Logo_-_Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/","url":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/","name":"Axonics Provides Update on Inter Partes Review Proceedings - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240321796123\/en\/788134\/22\/Axonics_Logo_-_Color.jpg","datePublished":"2024-03-21T21:02:26+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240321796123\/en\/788134\/22\/Axonics_Logo_-_Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240321796123\/en\/788134\/22\/Axonics_Logo_-_Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/axonics-provides-update-on-inter-partes-review-proceedings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Axonics Provides Update on Inter Partes Review Proceedings"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59082"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59082\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}